Fact Sheet for Healthcare Providers: REGIOCIT: A Replacement Solution that Contains Citrate for Regional Citrate Anticoagulation (RCA) of the Extracorporeal Circuit [open pdf - 104KB]
From the Document: "The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, REGIOCIT [sodium chloride and sodium citrate renal replacement and regional anticoagulant solution]: a replacement solution that contains citrate for Regional Citrate Anticoagulation (RCA) of the extracorporeal circuit. REGIOCIT has been authorized for emergency use as a replacement solution in adult patients treated with Continuous Renal Replacement Therapy (CRRT), and for whom RCA is appropriate, during the COVID-19 [coronavirus disease 2019] pandemic. REGIOCIT is intended for use in a critical care setting. REGIOCIT is intended to be used in continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF) modalities. Use of REGIOCIT is limited to healthcare providers and/or institutions that Baxter has qualified to administer REGIOCIT for these emergency uses."
U.S. Food and Drug Administration: https://www.fda.gov/